Zhen Cheng Selected Research

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid

1/2020	Synthesis and Application of a Long-Circulating Radiolabeled Peptide for Targeting of Osteosarcoma.
10/2019	PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
7/2015	PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule.
11/2014	Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors.
7/2012	In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.
6/2011	Macrocyclic chelator assembled RGD multimers for tumor targeting.
3/2011	Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
11/2010	PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide.
6/2010	64Cu-labeled affibody molecules for imaging of HER2 expressing tumors.
5/2010	Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhen Cheng Research Topics

Disease

153	Neoplasms (Cancer) 11/2022 - 02/2002
20	Melanoma (Melanoma, Malignant) 01/2021 - 02/2002
10	Glioblastoma (Glioblastoma Multiforme) 11/2022 - 11/2005
9	Breast Neoplasms (Breast Cancer) 01/2022 - 05/2007
9	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 02/2012
8	Glioma (Gliomas) 01/2022 - 10/2005
8	Inflammation (Inflammations) 01/2021 - 01/2012
7	Carcinogenesis 01/2022 - 01/2011
7	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 07/2012
6	Neoplasm Metastasis (Metastasis) 01/2021 - 10/2005
5	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 04/2014
5	Carcinoma (Carcinomatosis) 10/2019 - 06/2012
4	Liver Neoplasms (Liver Cancer) 01/2022 - 03/2014
4	Glomerulonephritis 01/2021 - 09/2016
4	Atherosclerotic Plaque (Atheroma) 01/2020 - 01/2012
4	Lung Neoplasms (Lung Cancer) 08/2019 - 02/2012
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2022 - 01/2018
3	Osteoporosis 12/2021 - 01/2018
3	IGA Glomerulonephritis (IGA Nephropathy) 05/2020 - 12/2017
3	Rupture 01/2020 - 06/2015
3	Disease Progression 01/2020 - 01/2016
3	Myocardial Infarction 01/2020 - 01/2014
3	Hypogonadism (Hypergonadotropic Hypogonadism) 01/2019 - 12/2016
3	Stroke (Strokes) 01/2018 - 06/2015
3	Atherosclerosis 10/2016 - 01/2012
2	Amyloidosis 11/2022 - 01/2021
2	Brain Neoplasms (Brain Tumor) 11/2022 - 02/2015
2	Hyperthermia 07/2022 - 02/2022

Drug/Important Bio-Agent (IBA)

45	Peptides (Polypeptides)IBA 06/2021 - 02/2002
28	IntegrinsIBA 10/2019 - 10/2005
23	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2008
20	Molecular Probes (Molecular Probe)IBA 01/2021 - 05/2005
19	ErbB Receptors (EGF Receptor)IBA 01/2021 - 05/2008
15	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2020 - 02/2002
14	Pharmaceutical PreparationsIBA 01/2022 - 05/2006
13	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2009
13	Radioisotopes (Radionuclides)IBA 01/2021 - 02/2002
11	Melanins (Melanin)IBA 01/2021 - 10/2009
10	Coloring Agents (Dyes)IBA 09/2022 - 05/2010
10	Cystine-Knot MiniproteinsIBA 10/2019 - 03/2009
9	arginyl-glycyl-aspartic acidIBA 11/2014 - 10/2005
8	Contrast MediaIBA 06/2020 - 01/2011
8	Cystine (L-Cystine)IBA 10/2019 - 02/2010
6	EnzymesIBA 10/2020 - 06/2011
6	GoldIBA 10/2020 - 04/2013
6	CY5.5 cyanine dyeIBA 01/2020 - 05/2006
6	LigandsIBA 01/2019 - 07/2013
6	Bombesin Receptors (Bombesin Receptor)IBA 01/2018 - 06/2012
6	MetalsIBA 01/2017 - 02/2002
6	Type 1 Melanocortin ReceptorIBA 03/2014 - 05/2007
5	IronIBA 01/2022 - 02/2011
5	Therapeutic UsesIBA 01/2021 - 06/2014
5	AcidsIBA 01/2018 - 03/2009
5	Indicators and Reagents (Reagents)IBA 10/2016 - 10/2005
5	RheniumIBA 12/2010 - 02/2002
5	alpha-MSHIBA 11/2009 - 02/2002
4	Arginine (L-Arginine)FDA Link 10/2020 - 04/2010
4	Monoclonal AntibodiesIBA 01/2020 - 08/2014
4	Biological ProductsIBA 01/2020 - 06/2005
4	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 01/2020 - 09/2011
4	Glucose (Dextrose)FDA LinkGeneric 10/2019 - 05/2006
4	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2019 - 04/2016
4	Fluorescent Dyes (Fluorescent Probes)IBA 10/2018 - 11/2005
4	Chelating AgentsIBA 01/2017 - 06/2011
4	PeptidomimeticsIBA 01/2012 - 12/2009
3	Tyrosine Kinase InhibitorsIBA 05/2022 - 01/2018
3	IonsIBA 01/2022 - 09/2015
3	CreatinineIBA 10/2021 - 09/2012
3	Immunoglobulin A (IgA)IBA 01/2021 - 12/2017
3	AntigensIBA 01/2021 - 04/2014
3	CytokinesIBA 01/2020 - 11/2011
3	Human Serum Albumin FDA LinkGeneric 01/2020 - 01/2012
3	AminesIBA 08/2019 - 06/2005
3	Testosterone (Sustanon)FDA Link 01/2019 - 12/2016
3	Urokinase Plasminogen Activator ReceptorsIBA 11/2018 - 07/2013
3	1-phenyl-3,3-dimethyltriazene (PDT)IBA 04/2017 - 11/2015
3	CathepsinsIBA 10/2016 - 01/2011
3	Cysteine (L-Cysteine)FDA Link 10/2016 - 01/2011
3	Tumor Biomarkers (Tumor Markers)IBA 06/2016 - 05/2008
3	Aspartic Acid (Aspartate)FDA Link 01/2016 - 04/2010
3	Firefly LuciferasesIBA 06/2014 - 05/2007
3	Thymidine KinaseIBA 06/2014 - 01/2006
3	BombesinIBA 12/2013 - 06/2012
3	Agouti-Related ProteinIBA 02/2013 - 02/2010
3	acetyl0Nle(4)-Asp(5)-Phe(7)- alpha-MSH (4-11)IBA 11/2012 - 05/2007
3	Integrin alphaVbeta3IBA 02/2010 - 10/2005

Therapy/Procedure

58	Therapeutics 02/2022 - 10/2005
13	Precision Medicine 11/2022 - 05/2014
9	Quantum Dots (Quantum Dot) 09/2018 - 09/2008
8	Computer-Assisted Surgery (Image Guided Surgery) 11/2022 - 05/2017
8	Drug Therapy (Chemotherapy) 10/2020 - 02/2012
6	Photothermal Therapy 02/2022 - 03/2014
6	Immunotherapy 01/2022 - 05/2016
5	Lasers (Laser) 01/2018 - 11/2012
4	Transplantation 10/2021 - 12/2006
4	Photochemotherapy (Photodynamic Therapy) 04/2017 - 03/2014
3	Ligation 01/2020 - 06/2015
3	Radiotherapy 01/2018 - 02/2002
3	Intravenous Injections 10/2016 - 01/2006
3	Intravenous Administration 03/2014 - 01/2006